What is it about?
This study investigates the clinical impact of hepatitis B virus (HBV) on hospitalizations in Spain from 1997 to 2017, focusing on the effects of potent oral nucleos(t)ide therapies, such as entecavir and tenofovir, introduced in 2007.
Featured Image
Photo by Fusion Medical Animation on Unsplash
Why is it important?
The importance of this study lies in its insights into the clinical and public health challenges posed by hepatitis B virus (HBV) infection, particularly in the context of Spain. This research is crucial for guiding public health policies, improving clinical management of HBV, and addressing unmet needs such as HDV treatment and HCC prevention.
Perspectives
The perspectives of the paper "Impact of Potent Nucleos(t)ide Therapy on Hepatitis B Hospitalisations in Spain" focus on the clinical, public health, and research implications of hepatitis B virus (HBV) management over two decades. While potent antivirals have improved outcomes for many HBV patients, challenges such as rising HCC rates, HDV management, late diagnoses, and an aging patient population persist. These findings highlight the need for comprehensive public health strategies, enhanced screening programs, and continued research to address these gaps effectively.
Octavio Corral Pazos de Provens
Universidad Internacional de La Rioja
Read the Original
This page is a summary of: Impact of potent nucleos(t)ide therapy on hepatitis B hospitalisations in Spain, Alimentary Pharmacology & Therapeutics, November 2022, Wiley,
DOI: 10.1111/apt.17280.
You can read the full text:
Contributors
The following have contributed to this page
